Sat, Oct-21-23, 08:37
|
 |
Forum Founder
Posts: 37,263
|
|
Plan: LC, GF
Stats: 241/186/140
BF:
Progress: 54%
Location: Eastern ON, Canada
|
|
Nestlé rides Ozempic boom with new ‘companion’ candy for weight loss drugs
Words fail 
Quote:
Nestlé rides Ozempic boom with new ‘companion’ candy for weight loss drugs
October 20, 2023, 3:54 PM ET
Nestlé, the world’s largest food and beverage company, is jumping on the Ozempic boom with a new candy that aims to be a perfect companion for weight loss drugs. This move comes as the demand for weight loss products continues to surge, driven by increasing health consciousness and the desire to maintain a healthy weight.
Ozempic is a drug developed by pharmaceutical company Novo Nordisk, known for its effectiveness in assisting patients with type 2 diabetes in managing their blood sugar levels and losing weight. Nestlé, seeing an opportunity in this market, has partnered with Novo Nordisk to create a candy that complements the effects of Ozempic.
Named “SlimBites,” these candies are specially formulated with ingredients that aim to enhance the weight loss benefits of Ozempic. They contain a blend of natural extracts such as green tea, citrus fruits, and Garcinia Cambogia, which are believed to have fat-burning properties. Additionally, SlimBites are made with low-calorie sweeteners such as stevia and erythritol to provide a guilt-free treat for consumers.
The idea behind SlimBites is to provide users with a convenient snack option that not only satisfies their sweet cravings but also aligns with their weight loss journey. By combining the effects of Ozempic with SlimBites, Nestlé hopes to tap into the growing market of consumers who are looking for effective weight loss solutions.
Nestlé’s partnership with Novo Nordisk is a strategic move that leverages the expertise of both companies. While Novo Nordisk specializes in developing pharmaceuticals that target diabetes and weight management, Nestlé has a deep understanding of the consumer packaged goods industry. This collaboration allows Nestlé to expand its product portfolio and enter the weight loss segment, catering to the needs of health-conscious consumers.
The success of Ozempic has laid the foundation for SlimBites. With Novo Nordisk reporting significant growth in sales of Ozempic, Nestlé is confident that SlimBites will find a receptive consumer base. The demand for weight loss products has been on the rise, with more individuals seeking effective and convenient solutions to manage their weight. SlimBites, with its complementary effects to Ozempic, aims to meet this demand head-on.
However, it is important to note that while weight loss drugs like Ozempic can be effective in aiding weight loss efforts, they should always be used under the guidance of a healthcare professional. Weight loss is a complex process that involves a combination of healthy eating, exercise, and lifestyle changes. Candy, even if formulated with weight loss-friendly ingredients, should not be seen as a sole solution for weight management.
Nonetheless, the introduction of SlimBites by Nestlé adds an interesting twist to the weight loss industry. By combining the science behind weight loss drugs with the convenience and indulgence of candies, Nestlé aims to provide consumers with a unique offering. It will be interesting to see how the market responds to this innovative approach and whether SlimBites can carve a niche for itself in the competitive weight loss market.
Nestlé wants to make your weight loss journey a little more fun.
People trying to lose weight are most likely trying to avoid chocolate as best they can, and with the craze surrounding Ozempic and other weight-loss medications, more and more people are likely to stop adding sweets to their shopping carts.
But Nestlé announced on Thursday that the company was working on ‘companion products’ for weight-loss drugs such as Ozempic, Wegovy and Mounjaro.
Nestlé CEO Mark Schneider said there is a market for products that help people taking appetite suppressant medications get the nutrients, minerals and nutrients they need while still supporting weight loss.
The “companion products” could also help “limit loss of lean muscle mass” and “rapid weight gain” – especially since the drugs are not a “permanent” solution, Schneider told Bloomberg.
The Swiss food giant is also working on smaller portion sizes for their goods and already sells weight loss products such as Optifast meal replacements.
Ozempic is a drug designed for people with type 2 diabetes and is widely used as a weight loss drug.
Ozempic and Wegovy are semaglutides, which help the pancreas release the right amount of insulin when blood sugar levels are high. Its Eli Lilly counterpart Mounjaro is a tirzepatide that has also been shown to help control blood sugar levels.
The drugs work by mimicking a natural hormone, GLP-1, which slows the passage of food through the stomach, helping people feel full longer.
Although both Ozempic and Wegovy are commonly used for weight loss today, only Wegovy is approved by the Food and Drug Administration for weight loss.
But don’t worry: anyone who wants to indulge in sweet treats can still do so.
Schneider reaffirmed that the majority of Nestlé products “will not be affected” by the increase in the use of weight-loss drugs, but that they will monitor “carefully” to see if product demand is affected.
The news comes after it was reported that Nestlé shares fell as much as 3.6% on Thursday and the company’s shares fell 6% in the past month – and there are concerns that the weight-loss drugs are partly the reason.
https://www.chof360.co.uk/nestle-ri...ght-loss-drugs/
|
|
Threaded Mode